Sirona Medical, a provider of cloud-native radiology software, has entered into a distribution and collaboration partnership with RevealDX to enhance lung cancer screening.

RevealDX is a computer-assisted diagnostic (CADx) software company focused on improving lung cancer outcomes using non-invasive diagnosis.

In addition, Sirona has integrated Nines’ FDA-approved automated measurement tool, which it has recently acquired, to improve its end-to-end care for patients with lung nodules.

First announced in 2021, the partnership will enable RevealDx to integrate its CE-marked RevealAI-Lung algorithm into Sirona’s unified radiology platform.

The integrated solution is expected to help radiologists easily implement the AI model into practice, with FDA approval anticipated in early 2023.

Sirona Medical founder and CEO Cameron Andrews said: “Sirona is re-architecting radiology IT from first principles, allowing powerful software tools like artificial intelligence to finally have the transformational impact on clinical radiology that they should.

“Our partnership with RevealDX illustrates Sirona’s broader ambition by giving 3rd party developers the tools to embed AI deeply into every aspect of the clinical workflow, Sirona can deliver tools to radiologists that help them practice more effectively, efficiently, and profitably.”

“AI will be the key to radiology’s value-based future – giving radiologists the tools to amplify their impact on downstream healthcare, and payers the mechanism to finally quantify and incentivise quality effectively.”

Sirona’s core platform provides a cloud-native workflow solution for viewing, reporting, universal worklist, and PACS archive in a unified zero-footprint format.

When integrated with RevealDX lung workflow, the company’s platform can be deployed as an overlay to the practices’ existing PACS & RIS systems.

US-based private radiology practices Hackensack Radiology Group (HRG) and Triad Radiology Associates (TRA) have partnered with Sirona.

They will use the company’s comprehensive solution after production testing early next year, and to develop additional tools to enhance lung cancer care for their patients.

RevealDx CEO Chris Wood said: “The cloud-native, scalable AI infrastructure of RevealDX and Sirona working together is the model that healthcare aspires to.

“Clinical studies show that a 29% reduction in false positives and a 45% increase in early diagnosis is possible with RevealAI-Lung. Our partnership with Sirona will allow us to efficiently deliver these benefits to customers.”

RevealDX chief medical officer and Triad Radiology Associates CEO Lauren Nicola said: “By uniquely integrating a high-value AI application into the radiologist viewer and reporter, we can achieve more efficient, better diagnoses, concisely communicated in structured, standardised format.”